GlassScriptPhysician profile
Lowell C Shinn
NPI 1811961451
$1,800.12
in general payments reported to CMS, 2019-2025
26 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $76.56 · 2021: $50.60 · 2022: $124 · 2023: $74.04 · 2024: $545 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.82 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $377.61 | 2019-2025 | |
| Pfizer INC. | $310.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.56 | 2024-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $116.16 | 2022-2024 | Xtandi |
| Celgene Corporation | $94.21 | 2024-2025 | Reblozyl, Opdivo |
| Aveo Pharmaceuticals, INC. | $60.92 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.29 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $54.90 | 2019-2023 | Calquence |
| Sumitomo Pharma America, INC. | $47.88 | 2023-2024 | Orgovyx |
| Kite Pharma, INC. | $47.58 | 2023-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $46.32 | 2025 | |
| Abbvie INC. | $43.35 | 2024-2025 | |
| Incyte Corporation | $37.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.27 | 2025 | Enhertu, Datroway |
| Array Biopharma INC | $33.01 | 2024-2025 | Braftovi, Xalkori, Lorbrena |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $28.88 | 2021-2024 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $25.44 | 2022 | |
| Mirati Therapeutics, INC. | $23.59 | 2024 | Krazati |
| Gilead Sciences, INC. | $21.74 | 2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $17.99 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $17.99 | 2020 | |
| Nuvation Bio INC. | $16.63 | 2025 | Ibtrozi |
| Genzyme Corporation | $16.51 | 2019 | |
| Glaxosmithkline, LLC. | $15.90 | 2024 | Ojjaara |
| Emd Serono, INC. | $15.48 | 2019 | |
| Foundation Medicine, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Shinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.